Genelux Corporation (GNLX) Stock

Genelux Corporation (GNLX) is a Healthcare stock trading at $2.71 (as of 2026-08-21), with a market capitalization of $122.61M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Understand Genelux Corporation: how it makes money

Genelux develops oncolytic viral immunotherapies for hard-to-treat solid tumors, with Olvi-Vec as its lead candidate, and it makes money through future sales only if clinical programs translate into approved, commercial therapies.

As a clinical-stage biopharmaceutical company, its path to profit is fundamentally tied to whether clinical trial results for its pipeline candidates (especially Olvi-Vec) are strong enough to progress and ultimately support commercialization.

Business quality (Weak): Clear pipeline focus on oncolytic viral immunotherapies, but the provided data points are trial-level signals (response rates, disease control, progression-free survival) and there is no segment breakdown to show an established revenue engine yet.

Bull case

  • Positive early efficacy signals for Olvi-Vec in small cell lung cancer: In the Phase 1b/2 small cell lung cancer trial, the Overall Response Rate is 33% (and 67% in Cohort 4), with Disease Control Rate at 67%.
  • Durability signal in long-term follow-up: Progression-Free Survival in the long-term follow-up patient in the same Phase 1b/2 trial is 12.1 (ratio).

Bear case

  • Trial readouts may be based on small patient counts: The same Phase 1b/2 trial lists 9.0 evaluable patients, which can make results more sensitive to patient selection and cohort composition.
  • Performance could vary by line of therapy: Progression-Free Survival measured as the ratio in the immediately preceding line for the same patient is 1.9, versus 12.1 in long-term follow-up.
Valuation — source: SEC EDGAR (first-party)
Price$2.71
Market Cap$122.61M
Price / Book7.61
Price / Sales189.22
FCF Yield-39.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$8000.00
Net Margin-401812.5%
Revenue Growth (YoY)0.0%
EPS Growth (YoY)-9.5%
FCF Growth (YoY)22.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-16.33 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($6.76M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOThomas D. Zindrick
Employees24
CountryUS
IPO Date2023-01-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Spruce Biosciences, Inc. (SPRB)
  • TuHURA Biosciences, Inc. (HURA)
  • Anixa Biosciences, Inc. (ANIX)
  • Inovio Pharmaceuticals, Inc. (INO)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • Cumberland Pharmaceuticals Inc. (CPIX)
  • Coya Therapeutics, Inc. (COYA)
  • Rafael Holdings, Inc. (RFL)
GNLX earnings history · GNLX institutional & insider holders · GNLX KPIs & operating metrics · GNLX financials · GNLX investor presentations & press releases · GNLX SEC filings · GNLX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.